As South Korea's pharmaceutical industry continues to expand its global presence through innovation-driven drug development, Hanmi Pharm is reinforcing its position with a series of notable research and development (R&D) achievements. Following a major licensing agreement with U.S. pharmaceutical giant Eli Lilly, the company has also unveiled a next-generation obesity drug candidate, highlighting its growing ambitions in rare diseases and metabolic disorders.
In the global pharmaceutical industry, the value of a biotech company is increasingly measured not only by the size of its pipeline but also by whether leading multinational drugmakers recognize its technology through strategic partnerships and licensing agreements. Against this backdrop, Hanmi Pharm's recent accomplishments are drawing attention as an example of the rising competitiveness of South Korea's biopharmaceutical sector.
Earlier this month, Hanmi Pharm signed a global licensing agreement with Eli Lilly for Sonefpeglutide (HM15912), a long-acting GLP-2 analog being developed to treat Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases.
The agreement, valued at up to $1.26 billion (approximately KRW 1.9 trillion), includes a non-refundable upfront payment of $75 million. Under the deal, Eli Lilly obtains exclusive worldwide development, manufacturing, and commercialization rights outside South Korea.
Short Bowel Syndrome is a rare condition that develops after a significant portion of the small intestine is surgically removed, often due to Crohn's disease or cancer. Patients suffer from severe nutrient malabsorption and frequently require long-term parenteral nutrition, making the disease an area of substantial unmet medical need.
Industry observers note that the agreement represents more than a single licensing transaction. It also serves as another validation of Hanmi Pharm's proprietary LAPSCOVERY platform, a long-acting biologics technology designed to extend the therapeutic duration of peptide and protein drugs. The deal demonstrates that Korean-developed platform technologies continue to gain recognition among global pharmaceutical companies.
Hanmi Pharm is also expanding its presence in one of the industry's fastest-growing therapeutic areas—obesity treatment.
While GLP-1-based therapies have transformed obesity management by delivering significant weight loss, researchers have increasingly focused on one of their key limitations: the accompanying loss of lean muscle mass. Preserving skeletal muscle while reducing body fat has emerged as one of the next major competitive frontiers in obesity drug development.
Reflecting this trend, Hanmi Pharm recently introduced LA-MSTN (HM500197) at the American Diabetes Association (ADA) 2026 Scientific Sessions held in New Orleans.
HM500197 is a peptide-based candidate designed to selectively inhibit myostatin, a protein that regulates muscle growth. Unlike many competing programs based on monoclonal antibodies or Fc-fusion proteins, Hanmi's peptide platform is expected to offer greater flexibility for combination therapy or fixed-dose combinations with incretin-based obesity medicines.
According to the company, preclinical studies demonstrated that HM500197 achieved myostatin inhibition comparable to antibody-based therapies while maintaining high target selectivity with minimal off-target cytokine activity.
Animal studies also showed dose-dependent increases in lean body mass, particularly skeletal muscle, while combination therapy with GLP-1 drugs reduced muscle loss and promoted fat-focused weight reduction.
Hanmi Pharm additionally presented new research on LA-UCN2 (HM17321), another muscle-enhancing obesity therapy currently undergoing Phase 1 clinical trials in the United States. The candidate is designed to simultaneously promote fat reduction, muscle growth, and improvements in physical performance and metabolic function.
At ADA 2026, the company presented seven additional studies highlighting HM17321's potential applications in musculoskeletal health, cardiovascular protection, kidney function, and combination treatment strategies.
Hanmi Pharm currently maintains a portfolio of more than 20 innovative drug candidates spanning obesity and metabolic diseases, oncology, and rare diseases. The company has consistently invested a significant portion of its annual revenue into R&D, positioning innovation as a core long-term growth strategy.
Industry experts caution, however, that licensing agreements represent only one milestone in the drug development process. Commercial success ultimately depends on clinical trial outcomes, regulatory approvals, and successful global commercialization.
Nevertheless, Hanmi Pharm's recent licensing success and expanding obesity pipeline illustrate how Korean pharmaceutical companies are increasingly competing not only through manufacturing capabilities but also through proprietary innovation and advanced drug discovery technologies. As the global obesity treatment market evolves beyond simple weight reduction toward therapies that improve overall metabolic health and preserve muscle mass, Hanmi Pharm's differentiated pipeline will likely remain under close industry observation.
